Ann: Successful Delivery of CRIPR/Cas9 into Cells ex vivo, page-18

From what I can gather the first 80-90% of Phylogicas life the people running the company were almost exclusively researchers or fund managers. The last 10-20% has been run by commercial people and personal shareholders. All the way along the science has developed but I gather the strategy changed or was unclear. In fairness to the predecessors they got us to where we are and I acknowledge that but the current group seem very clear on what they are saying and what they are doing. Let’s look back and judge rather than look forward and predict repetition. There is no one in the Board or management who have a vested interest in dragging this out. 2019 is the year and with live MTAs in place with commercial outcomes and data dropping I am not ruling out one of those December deals.

It seems much harder to get stock all of a sudden.